Khan, Mohammad Ashrafuddin El-Gamal, Mohammed I. Oh, Chang-Hyun 2024-01-20T02:04:21Z 2024-01-20T02:04:21Z 2022-01-10 2017-02 1389-5575 https://pubs.kist.re.kr/handle/201004/123103 B-RAF gene is a component of the MAPK pathway that plays a very important role in cell division, survival, proliferation, and many other cellular functions. Mutations of the B-RAF (such as V600E-B-RAF) lead to melanoma, which is one of the leading causes of death worldwide. R&D progress is being done aiming at improved therapy in the future. The existing melanoma therapy is left out with poor overall survival, drug resistance, and many side effects. With the recent approval of new drugs, there is a hope for melanoma patients for complete cure and better life quality. However, there is still a need for improved, safe, and complete therapy for advanced melanoma. This review describes melanoma caused by V600E-B-RAF gene mutation, its pathway, drugs available and recently approved drugs, and future prospects to be overcome. English BENTHAM SCIENCE PUBL LTD CYCLIN D1 EXPRESSION METASTATIC MELANOMA BRAF MUTATIONS BRAF(V600E) INHIBITION PTEN/MMAC1 ALTERATIONS DABRAFENIB GSK2118436 COMBINATION THERAPY ACQUIRED-RESISTANCE MALIGNANT-MELANOMA SIGNALING PATHWAY A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It Article 10.2174/1389557516666160622213142 1 MINI-REVIEWS IN MEDICINAL CHEMISTRY, v.17, no.4, pp.351 - 365 MINI-REVIEWS IN MEDICINAL CHEMISTRY 17 4 351 365 scie scopus 000399579900004 2-s2.0-85012067997 Chemistry, Medicinal Pharmacology & Pharmacy Review CYCLIN D1 EXPRESSION METASTATIC MELANOMA BRAF MUTATIONS BRAF(V600E) INHIBITION PTEN/MMAC1 ALTERATIONS DABRAFENIB GSK2118436 COMBINATION THERAPY ACQUIRED-RESISTANCE MALIGNANT-MELANOMA SIGNALING PATHWAY Cancer drug kinase inhibitors melanoma V600E-B-RAF